Earnings Call Transcript - Q4FY20 for Neuland Laboratories
Conference Call with Neuland Labs Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full transcript22-05-2020
22-05-2020
NEULAND LABORATORIES LTD. - 524558 - Compliances-Reg.24(A)-Annual Secretarial Compliance
With reference to the subject cited above and with reference to the Listing Regulations and afore-mentioned SEBI circular, please find enclosed the Annual Secretarial Compliance Certificate issued by the Company Secretary in Practice for the financial year ended March 31, 2020. This is for your information and records.22-05-2020
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attached a copy of the Press Release being issued by the Company and the same is being uploaded on the website of the Company. This is for your information and records.22-05-2020
NEULAND LABORATORIES LTD. - 524558 - Outcome Of Board Meeting
Please find enclosed the Audited Financial Results (Standalone & Consolidated) of the Company for the year ended March 31, 2020 under Ind AS, which have been approved and taken on record at a meeting of the Board of Directors of the Company held on even date. We would like to state that M/s. MSKA & Associates, Chartered Accountants (FRN: 105047W), Statutory Auditors of the Company, have issued audit reports with unmodified opinion on the aforementioned Audited Financial Results (enclosed). Further, the Board has approved the re-appointment of Mr. Davuluri Saharsh Rao, as a Whole-Time Director, designated as Joint Managing Director of the Company, for a period of five years with effect from June 1, 2020, subject to the approval of the shareholders at the ensuing Annual General Meeting. The meeting of the Board of Directors of the Company commenced at 11.30 A.M. and concluded at 03:00 P.M. This is for your information and records.22-05-2020
NEULAND LABORATORIES LTD. - 524558 - Audited Financial Results For Quarter And Financial Year Ended March 31, 2020
Audited Financial Results for Quarter and Financial Year ended March 31, 202022-05-2020
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Meeting Updates
We refer to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 and enclose a copy of the Q4 FY 2019-2020 Earnings Call details, for your information and records.18-05-2020
NEULAND LABORATORIES LTD. - 524558 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We are enclosing herewith the copies of newspaper publication on May 15, 2020, of the Notice of the meeting of Board of Directors scheduled to be held on Friday, May 22, 2020, inter-alia, to consider and take on record the Audited Financial Results of the Company for the year ended March 31, 2020.15-05-2020
NEULAND LABORATORIES LTD. - 524558 - Board Meeting Intimation for To Consider And Take On Record The Audited Financial Results Of The Company For The Year Ended March 31, 2020
NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2020 ,inter alia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 202014-05-2020
NEULAND LABORATORIES LTD. - 524558 - General Updates
We refer to our letter dated February 7, 2020 and would like to inform you that the Company has received an Establishment Inspection Report (EIR) from the U.S.FDA for its manufacturing facility located at Pashamylaram, Hyderabad. The facility was inspected from 3rd to 7th February 2020. The inspection has now been closed by the U.S. FDA. This is for your information and records.07-05-2020